Martin "M" Zenni M.D.

Associate Professor & Medical Director, Cardiovascular Off Campus Outreach Program; Medical Director of Nuclear Cardiology

Department: Department of Medicine

Business Phone: (904) 244-2655

Business Email: martin.zenni@jax.ufl.edu

Appointments and Locations

Board Certifications

Internal Medicine
Cardiovascular Disease
Interventional Cardiology
Nuclear Cardiology

Clinical Profile

Specialties

Cardiovascular Disease
Interventional Cardiology
Nuclear Cardiology

Interests

Clinical Special Interests: Coronary artery disease, atherosclerosis, hyperlipidemia and cardiac risk assessment; permanent pacemaker and hypothermia therapy for acute myocardial infarction; nuclear cardiology, antiplatelet and anticoagulant therapy
Research Special Interests: Coronary artery disease, atherosclerosis, hyperlipidemia and cardiac risk assessment, permanent pacemaker, and hypothermia therapy for acute myocardial infarction; nuclear cardiology, antiplatelet and anticoagulant therapy

Publications

2023

Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.

JACC. Cardiovascular interventions.16(1):36-46[DOI] 10.1016/j.jcin.2022.10.034.[PMID] 36317958.

3 citations·PubMed·Publisher's Site

2023

Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.18(15):1254-1265[DOI] 10.4244/EIJ-D-22-00719.[PMID] 36602868.

1 citations·PubMed·Publisher's Site

2022

Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.

European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.

2 citations·PubMed·Publisher's Site

2022

Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.

Journal of thrombosis and thrombolysis.54(3):461-469[DOI] 10.1007/s11239-022-02696-4.[PMID] 36048358.

2 citations·PubMed·Publisher's Site

2022

Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.

Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.

2 citations·PubMed·Publisher's Site

2022

Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.

European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.

2 citations·PubMed·Publisher's Site

2022

Swinging heart seen on single-photon emission computed tomography (SPECT).

BMJ case reports.15(6):-[DOI] 10.1136/bcr-2021-246487.[PMID] 35760503.

PubMed·Publisher's Site

2021

Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.

JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.

2 citations·PubMed·Publisher's Site

2020

Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.

Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.

17 citations·PubMed·Publisher's Site

2020

Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.

Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.

10 citations·PubMed·Publisher's Site

2020

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.

Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.

16 citations·PubMed·Publisher's Site

2020

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.

JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.

17 citations·PubMed·Publisher's Site

2019

Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.

JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.

23 citations·PubMed·Publisher's Site

2019

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.

JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.

12 citations·PubMed·Publisher's Site

2019

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.

82 citations·PubMed·Publisher's Site

2018

Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.

Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.

43 citations·PubMed·Publisher's Site

2017

Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.

Thrombosis and haemostasis.117(1):201-203[DOI] 10.1160/TH16-08-0594.[PMID] 27786340.

6 citations·PubMed·Publisher's Site

2017

Should endovascular approach be the first line of treatment for retroperitoneal bleeding with hemodynamic shock following percutaneous intervention? A case series.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.90(1):104-111[DOI] 10.1002/ccd.26775.[PMID] 27566914.

7 citations·PubMed·Publisher's Site

2016

A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.

European heart journal.37(35):2722-30[DOI] 10.1093/eurheartj/ehv744.[PMID] 26848148.

49 citations·PubMed·Publisher's Site

2016

Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.

Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.

88 citations·PubMed·Publisher's Site

2016

Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.

Thrombosis and haemostasis.115(3):622-31[DOI] 10.1160/TH15-06-0467.[PMID] 26633836.

21 citations·PubMed·Publisher's Site

2016

Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.

Thrombosis and haemostasis.116(6):1060-1069[DOI] .[PMID] 27488362.

7 citations·PubMed·Publisher's Site

2016

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.

Circulation.134(11):780-92[DOI] 10.1161/CIRCULATIONAHA.116.023402.[PMID] 27559041.

74 citations·PubMed·Publisher's Site

2016

Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.

JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.

31 citations·PubMed·Publisher's Site

2015

Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.

JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.

66 citations·PubMed·Publisher's Site

2015

Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.

JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.

4 citations·PubMed·Publisher's Site

2015

Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory.

Cardiovascular revascularization medicine : including molecular interventions.16(5):266-71[DOI] 10.1016/j.carrev.2015.05.011.[PMID] 26242981.

11 citations·PubMed·Publisher's Site

2014

Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.

Journal of cardiovascular translational research.7(1):53-63[DOI] 10.1007/s12265-013-9535-3.[PMID] 24395495.

21 citations·PubMed·Publisher's Site

2014

Operator radiation exposure and physical discomfort during a right versus left radial approach for coronary interventions: a randomized evaluation.

JACC. Cardiovascular interventions.7(7):810-6[DOI] 10.1016/j.jcin.2013.11.026.[PMID] 24954573.

30 citations·PubMed·Publisher's Site

2014

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

JACC. Cardiovascular interventions.7(4):426-34[DOI] 10.1016/j.jcin.2013.11.019.[PMID] 24630878.

27 citations·PubMed·Publisher's Site

2013

Effects of Cangrelor in Prasugrel Treated Patients: a Pharmacodynamic in Vitro Investigation

Circulation.128(22, S):-[DOI] .[PMID] .

PubMed·Publisher's Site

2013

Operator Radiation Exposure and Physical Discomfort During a Right Versus Left Radial Approach for Coronary Interventions: a Randomized Evaluation

Journal of the American College of Cardiology.61():E1683-[DOI] .[PMID] .

PubMed·Publisher's Site

2012

Effects of Pioglitazone On Platelet P2Y12 Mediated Signaling in Clopidogrel Treated Patients With Type 2 Diabetes Mellitus

Journal of the American College of Cardiology.59():E263-[DOI] .[PMID] .

PubMed·Publisher's Site

2012

Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.

Thrombosis and haemostasis.108(5):930-6[DOI] 10.1160/TH12-06-0397.[PMID] 22782352.

12 citations·PubMed·Publisher's Site

2012

Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients On Maintenance Prasugrel Therapy: Results of a Prospective Randomized Study

Journal of the American College of Cardiology.59():E270-[DOI] .[PMID] .

PubMed·Publisher's Site

2012

Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study.

Journal of the American College of Cardiology.59(19):1681-7[DOI] 10.1016/j.jacc.2011.12.039.[PMID] 22554598.

15 citations·PubMed·Publisher's Site

2012

Radial Access: Is There An Increased Risk of Operator Radiation Exposure During a Right Versus Left Radial Approach?

Journal of the American College of Cardiology.60():B117-[DOI] .[PMID] .

PubMed·Publisher's Site

2011

Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.

Thrombosis and haemostasis.106(2):253-62[DOI] 10.1160/TH11-01-0041.[PMID] 21614414.

33 citations·PubMed·Publisher's Site

2011

Transradial Approach To Coronary Interventions: How Steep Is the Learning Curve for Trained Interventional Cardiologists?

Journal of the American College of Cardiology.58():B141-B142[DOI] .[PMID] .

PubMed·Publisher's Site

2009

Antiplatelet Drug Response Variability and the Role of Platelet Function Testing: a Practical Guide for Interventional Cardiologists

Catheterization and cardiovascular interventions..73(1):1-14[DOI] 10.1002/ccd.21782.[PMID] 19089929.

28 citations·PubMed·Publisher's Site

2009

Clopidogrel-Induced Antiplatelet Effect Assessment By Flow Cytometry and Point-Of-Care Based Assays: Correlation Between Vasp and Verifynow P2Y(12) Testing

Journal of the American College of Cardiology.53():A71-[DOI] .[PMID] .

PubMed·Publisher's Site

2009

Evaluation of a Modified Light Transmittance Aggregometry Protocol To Assess P2Y(12) Blockade Induced By Clopidogrel

Journal of the American College of Cardiology.53():A71-[DOI] .[PMID] .

PubMed·Publisher's Site

2009

Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.

Thrombosis research.124(3):318-22[DOI] 10.1016/j.thromres.2008.10.001.[PMID] 19012950.

33 citations·PubMed·Publisher's Site

2008

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

European heart journal.29(18):2202-11[DOI] 10.1093/eurheartj/ehn287.[PMID] 18567918.

160 citations·PubMed·Publisher's Site

2008

A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgery.

Stroke.39(2):361-5[DOI] 10.1161/STROKEAHA.107.495010.[PMID] 18174484.

42 citations·PubMed·Publisher's Site

2008

Association of Heart Failure Class and Left Ventricular Dyssynchrony Measured By Spect Imaging in Ischemic Systolic Heart Failure Patients

Journal of Cardiac Failure.14(6):S90-[DOI] 10.1016/j.cardfail.2008.06.246.[PMID] .

PubMed·Publisher's Site

2008

Association of Ventricular Arrhythmia Therapy and Extent of Scarred Myocardium Measured By Single-Photon Emission Computed Tomography Imaging in Ischemic Systolic Heart Failure Patients

Journal of Cardiac Failure.14(6):S58-[DOI] 10.1016/j.cardfail.2008.06.306.[PMID] .

PubMed·Publisher's Site

2008

Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.

The American journal of cardiology.101(4):440-5[DOI] 10.1016/j.amjcard.2007.09.087.[PMID] 18312754.

61 citations·PubMed·Publisher's Site

2008

Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.

Thrombosis and haemostasis.99(1):161-8[DOI] 10.1160/TH07-09-0562.[PMID] 18217149.

65 citations·PubMed·Publisher's Site

2008

Impact of the Degree of Platelet Function On Thrombin Generation Profiles in Patients With Type 2 Diabetes Mellitus

Journal of the American College of Cardiology.51():A193-[DOI] .[PMID] .

PubMed·Publisher's Site

2008

Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents.

International journal of cardiology.130(3):444-8[DOI] 10.1016/j.ijcard.2007.08.143.[PMID] 18199506.

13 citations·PubMed·Publisher's Site

2007

Anatomical and physiologic assessments in patients with small coronary artery disease: final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial.

American heart journal.153(2):296.e1-7[DOI] .[PMID] 17239692.

47 citations·PubMed·Publisher's Site

2007

Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve.

Journal of the American College of Cardiology.50(6):514-22[DOI] .[PMID] 17678734.

105 citations·PubMed·Publisher's Site

2007

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.

Circulation.115(6):708-16[DOI] .[PMID] 17261652.

389 citations·PubMed·Publisher's Site

2006

Intravascular ultrasound characterization of the "black hole" phenomenon after drug-eluting stent implantation.

The American journal of cardiology.97(2):203-6[DOI] .[PMID] 16442364.

22 citations·PubMed·Publisher's Site

2005

Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry.

The Journal of invasive cardiology.17(8):396-8[DOI] .[PMID] 16079441.

11 citations·PubMed·Publisher's Site

2004

Multiple plaque morphologies in a single coronary artery: insights from volumetric intravascular ultrasound.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.61(3):376-80[DOI] .[PMID] 14988899.

10 citations·PubMed·Publisher's Site

2004

Synergistic use of sirolimus-eluting stents and intravascular ultrasound for the treatment of unprotected left main and vein graft disease.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.61(3):368-75[DOI] .[PMID] 14988898.

6 citations·PubMed·Publisher's Site

2003

Debulking does not benefit patients undergoing intracoronary beta-radiation therapy for in-stent restenosis: insights from the START trial.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.58(3):331-5[DOI] .[PMID] 12594697.

11 citations·PubMed·Publisher's Site

2002

Intravascular ultrasound catheter entrapment after coronary artery stenting.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.57(2):229-33[DOI] .[PMID] 12357527.

15 citations·PubMed·Publisher's Site